Fig. 3From: SGLT2 inhibition with empagliflozin improves coronary microvascular function and cardiac contractility in prediabetic ob/ob−/− miceAnalysis of a HbA1c b urine glucose levels, c urine creatine and d urine glucose/creatinine during the study. In the treated group (n = 22) HbA1c decreased, increased in ob/ob−/− untreated group (n = 21), and did not change in lean controls (n = 12) compared with baseline levels. Data were analyzed using repeated measure Anova with Tukey’s multiple comparisons test and are presented as mean with 95% confidence interval. *p < 0.05 and **p < 0.01 represents significant difference between lean controls and ob/ob−/− groups. ‡p ≤ 0.05 for ob/ob−/− treated and untreated groupBack to article page